The University of Southampton
University of Southampton Institutional Repository

Investigating the role of PIP4K in Immune System Regulation and P53-Inactivated Cancers

Investigating the role of PIP4K in Immune System Regulation and P53-Inactivated Cancers
Investigating the role of PIP4K in Immune System Regulation and P53-Inactivated Cancers
Phosphatidylinositol 5-phosphate 4-kinase (PIP4K) catalyses the formation of phosphatidylinositol 4,5 bisphosphate (PtdIns(4,5)P2) which is a messenger involved in important cellular signalling pathways including the PI3K/Akt/mTOR pathway and the phospholipase C pathway. Three isoforms of PIP4K have been identified, namely PIP4K2α, PIP4K2β, and PIP4K2, which have been shown to play roles in cellular activities such as growth, stress response, immune system regulation, and tumour formation. However, the exact mechanisms engaged by the kinases are still obscure. This study focused on investigating the role of PIP4K in modulating the immune system through regulatory T cells (Tregs), and in growth of cancer cells with inactivated p53. Findings from this study showed that PIP4K2β and 2 isoforms regulate PI3K/Akt/mTOR signalling in Tregs to control cell proliferation, survival, and immunosuppressive activity. This study also suggested that PIP4K controls FOXP3 expression, the master transcriptional regulator of Tregs through a novel PI3K/UHRF1/FOXP3 pathway. Previously PIP4K had been shown to play roles in cancer cell growth, and a discovery of possible synthetic lethal interaction with p53 in cancer cells has made this kinase a promising target for cancer therapy. Findings from this study indicate that the synthetic lethality of PIP4K and p53 is not present in all types of cancer. Rather, it is suggested to depend on the specific mutation of p53 and alteration in expression of PIP4K in the cells. Inhibition of PIP4K also regulates the PI3K/Akt pathway differently in different cancer cells. Together, findings from this study suggested that PIP4K modulates both the immune system and cancer cell growth, and its different role in regulating PI3K/Akt/mTOR pathway could be the key to understand how PIP4K modulates the systemic immune response, and how different cancers can benefit from the expression of this family of lipid kinases.
University of Southampton
Abdul Hamid, Shidqiyyah
7703bfce-0078-46ee-a33e-d467fbdca319
Abdul Hamid, Shidqiyyah
7703bfce-0078-46ee-a33e-d467fbdca319
Divecha, Nullin
5c2ad0f8-4ce7-405f-8a15-2fc4ab96d787

Abdul Hamid, Shidqiyyah (2021) Investigating the role of PIP4K in Immune System Regulation and P53-Inactivated Cancers. University of Southampton, Doctoral Thesis, 200pp.

Record type: Thesis (Doctoral)

Abstract

Phosphatidylinositol 5-phosphate 4-kinase (PIP4K) catalyses the formation of phosphatidylinositol 4,5 bisphosphate (PtdIns(4,5)P2) which is a messenger involved in important cellular signalling pathways including the PI3K/Akt/mTOR pathway and the phospholipase C pathway. Three isoforms of PIP4K have been identified, namely PIP4K2α, PIP4K2β, and PIP4K2, which have been shown to play roles in cellular activities such as growth, stress response, immune system regulation, and tumour formation. However, the exact mechanisms engaged by the kinases are still obscure. This study focused on investigating the role of PIP4K in modulating the immune system through regulatory T cells (Tregs), and in growth of cancer cells with inactivated p53. Findings from this study showed that PIP4K2β and 2 isoforms regulate PI3K/Akt/mTOR signalling in Tregs to control cell proliferation, survival, and immunosuppressive activity. This study also suggested that PIP4K controls FOXP3 expression, the master transcriptional regulator of Tregs through a novel PI3K/UHRF1/FOXP3 pathway. Previously PIP4K had been shown to play roles in cancer cell growth, and a discovery of possible synthetic lethal interaction with p53 in cancer cells has made this kinase a promising target for cancer therapy. Findings from this study indicate that the synthetic lethality of PIP4K and p53 is not present in all types of cancer. Rather, it is suggested to depend on the specific mutation of p53 and alteration in expression of PIP4K in the cells. Inhibition of PIP4K also regulates the PI3K/Akt pathway differently in different cancer cells. Together, findings from this study suggested that PIP4K modulates both the immune system and cancer cell growth, and its different role in regulating PI3K/Akt/mTOR pathway could be the key to understand how PIP4K modulates the systemic immune response, and how different cancers can benefit from the expression of this family of lipid kinases.

Text
FINAL Thesis Shidqiyyah Abdul-Hamid - Version of Record
Available under License University of Southampton Thesis Licence.
Download (6MB)
Text
Permission to deposit thesis - Shidqiyyah Abdul-Hamid ND HW - Other
Restricted to Repository staff only

More information

Published date: May 2021

Identifiers

Local EPrints ID: 450219
URI: http://eprints.soton.ac.uk/id/eprint/450219
PURE UUID: f78e3ce8-3313-4d16-a70b-44f3ea1e9112

Catalogue record

Date deposited: 16 Jul 2021 16:31
Last modified: 17 Mar 2024 06:43

Export record

Contributors

Author: Shidqiyyah Abdul Hamid
Thesis advisor: Nullin Divecha

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×